Neuroone Medical Technologies CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
NeuroOne Medical Technologies Corporation filed its Form 10-Q for the quarter ended June 30, 2026, detailing revenue increases but also significant operating losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
NASDAQ
NeuroOne Medical Technologies Corporation filed an amended 10-Q to correct revenue recognition errors that overstated product revenue and gross profit by $529,000 and $296,000, respectively.
NASDAQ
NeuroOne Medical Technologies reported increased product revenue in Q1 2026, though net loss widened due to license revenue recognition in the prior year.
NASDAQ
NeuroOne Medical Technologies Corporation reported a net loss of $1.44 million in Q1 2026, a significant decline from the prior year's profit, alongside ongoing Nasdaq compliance issues and substantial doubt about its ability to continue as a going concern.
NASDAQ
NeuroOne Medical Technologies reports significant revenue growth and reduced net losses, fueled by its Zimmer partnership and recent capital raise.
NASDAQ
NeuroOne Medical Technologies Corporation reports increased product revenue and gross profit for the quarter ended March 31, 2025, driven by OneRF product sales, while still facing net losses and reliance on additional financing.
NASDAQ
10-Q: NeuroOne Reports Q1 2025 Results: Revenue Soars on Zimmer Agreement, Faces Going Concern Uncertainty
NeuroOne Medical Technologies reports a significant increase in revenue for the quarter ended December 31, 2024, driven by a licensing agreement with Zimmer, but acknowledges substantial doubt about its ability to continue as a going concern.
NASDAQ
10-Q: NeuroOne Medical Technologies Reports Q3 2024 Results, Secures Lease Extension and New Financing
NeuroOne Medical Technologies Corporation announced its Q3 2024 financial results, a lease amendment extending their headquarters term, and new financing through a private placement and term loan facility.
NASDAQ
NeuroOne Medical Technologies Corporation reported a significant increase in product revenue for the quarter ended March 31, 2024, but continues to operate at a loss and faces substantial doubt about its ability to continue as a going concern.
NASDAQ
NeuroOne Medical Technologies Corporation reports a significant increase in product revenue for the quarter ended December 31, 2023, alongside ongoing development and commercialization efforts.